420 Lexington Avenue, Suite 2550, New York, NY 10170 800.925.2870 www.healthsharesinc.com

Emerging Cancer ETF

HealthShares™ Emerging Cancer ETF (HHJ) is one in a series of HealthShares[™] ETFs that are organized Vertically by therapeutic categories in pharmaceuticals, healthcare services, life sciences and biotechnology. HHJ seeks investment results that correspond to the performance before the Fund's fees and expenses, of HealthShares™ Emerging Cancer Index, an equity index of publicly traded common stocks and ADRs. The Emerging Cancer Index invests in pharmaceutical or biotechnology companies that have been identified as emerging cancer companies. Companies included in the Emerging Cancer Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of cancers. Companies in this index generally include those with some level of revenues, or those on the verge of revenues with significant but focused research and development programs. The companies in the universe are selected using a proprietary methodology developed by XShares Group LLC designed to identify companies in a specific healthcare vertical or sub-sector.

HHJ employs a low-cost passive management investment approach designed to track the performance of the HealthShares™ Emerging Cancer Index. HHJ will generally invest at least 90% of its assets in common stocks of companies in the underlying Index.

HHJ intends to pay out any dividends from its net investment income annually, and plans to distribute any net capital gains annually.

XShares Advisors LLC is the investment advisor. Bank of New York acts as custodian and administrator.

■ ETF Performance & Index History (%) (Through March 31, 2007)

| | | YTD | 1 Year | 3 Year | 5 Year | Inception |
|-------|---------------------------|-------|--------|--------|--------|-----------|
| Index | Index | 3.95% | -6.08% | -7.84% | -5.31% | -4.62% |
| | S&P 500 Healthcare Sector | 0.42% | 5.59% | 3.83% | 0.36% | -1.23% |
| ETF | NAV | | | | | 0.45% |
| | After Tax Held | | | | | 0.45% |
| | After Tax Sold | | | | | 0.27% |
| | Share Price Return | | | | | - 0.57% |

Performance data quoted represents past performance; past performance does not guarantee future results; and the investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost; and current performance may be lower or higher than the performance data quoted. To obtain the most recent month-end performance data call 800.925.2870.

Index performance does not represent fund performance. Indexes are unmanaged. You cannot invest in an index. A fund may perform significantly differently. Performance assumes dividend reinvestment; however these figures do not include management fees, transaction costs, taxes or other charges that would be incurred by a Fund or brokerage commissions in Fund shares, including transaction costs that a fund would incur. Such expenses and charges would reduce returns. Index returns are for illustrative purposes only and do not represent actual performance of HealthShares™ ETFs.

- The Inception date for the Indexes is September 22, 2006. The time period selected for the back tested data was for the 5 year period prior to the date that each Index was published. This 5 year time period was selected based upon general knowledge of the intense capital markets and merger activity within the healthcare and biotechnology industries. Pursuing a further back test would be less meaningful as many of the current constituents did not exist and many that may have qualified are no longer independent or currently traded. The Index Methodology used in the creation of the indexes can be found at www.healthsharesinc.com.
- The performance figures presented include "back tested data" (i.e. calculations of ho w an index might have been performed in the past if it had existed). Performance information prior to September 22, 2006 presented herein for the HealthShares ™ Indexes is based on hypothetical back tested data for the specific time periods shown and was not calculated in real time by an independent calculation agent. Hypothetical back tested performance has inherent limitations. No representation is being made that any investment performance will achieve performance similar to those shown. All information is being provided strictly for educational and illustrative purposes only. The information provided is not intended for trading purposes, and should not be considered investment advice.

An Investor should consider the fund's investment objective, risks, charges and expenses carefully before investing. For this and more complete information about the fund call 800.925.2870 or visit the website www.healthsharesinc.com for a prospectus. Please read the prospectus carefully before investing.

There are risks involved with investing in ETFs including possible loss of money. HealthShares ™ are not actively managed and are subject to risks similar to stocks, including those related to short selling and margin maintenance. HealthShares ™ ETFs are subject to increased risks associated with investing in a specific sector compared to a more diversified investment, as well as unique risks associated with the healthcare and biotechnology sector (i.e., government regulation, patent regulation, etc.). The prospectus is not an offer to buy or sell the portfolio shares, nor is the fund soliciting an offer to buy its shares in any jurisdiction where the offer or sale is not permitted.

NYSE:HHJ

| ■ ETF Information | 111 | | | |
|---|--------------------------|--|--|--|
| Initial Share Price | \$25.00 | | | |
| IOPV* Ticker Symbol | HHJ.IV | | | |
| CUSIP | 42226E406 \$24.78 | | | |
| NAV 3/31/07 | | | | |
| Gross Expense Ratio | 1.09% | | | |
| Net Expense Ratio | 0.75% | | | |
| Inception Date | 1/23/07 | | | |
| The advisor has agreed to cap its fees Index Information | to 0.75% through 9/30/20 | | | |
| Index Creator | XShares Group LLC | | | |
| Inception Date | 9/22/06 | | | |
| Investment Objective | Capital Appreciation | | | |
| Reuters Index Symbol | .HSMIDC | | | |
| ■ Capitalization Wei as of 3/21/07 | ghtings ▮ | | | |
| Large-Cap | 9.09% | | | |
| Mid-Cap | 0.00% | | | |
| Small-Cap | 90.91% | | | |
| Average Market Cap (Mil. \$) | \$ 1,519 | | | |
| ■ Technical Data | 111 | | | |
| Shares Outstanding | 300,200 | | | |
| Market Capitalization | \$6,735,000 | | | |
| Beta | 0.02 | | | |
| Treynor Ratio | -1.95 | | | |
| Sharpe Ratio | -0.10 | | | |

- 1. All calculations assume a Risk Free Rate of 4.5%
- 2. Beta is measured against the S&P 500.
- All risk calculations are derived from the arithmetic mean of daily returns and assume 250 trading days per year.
- All risk calculations have been computed since 12/15/2000, the date the index was first calculated.
- Beta is a measure of relative risk and is the slope of regression Sharpe is the risk adjusted return and is the return less the risk free rate divided by the standard deviation. Treynor is the risk adjusted return and is the return less the risk free rate divided by Beta.

| ■ Holdings* as of 3/21/07 | | | | | | | |
|---------------------------|----------------------------------|--------|----------|---------------------|------------------------------------|--|--|
| Weighting (%) | Name | Ticker | Exchange | Closing Price \$ | Market Capitalization (Mil. \$) | | |
| 4.6886 | ADVENTRX PHARMACEUTICALS INC COM | ANX | AMEX | 2.09 | \$216 | | |
| 3.6655 | AETERNA ZENTARIS INC | AEZS | NASDAQ | 3.28 | \$190 | | |
| 3.1944 | ARIAD PHARMACEUTICALS INC | ARIA | NASDAQ | 4.36 | \$291 | | |
| 7.9147 | ARRAY BIOPHARMA INC | ARRY | NASDAQ | 12.34 | \$490 | | |
| 4.3949 | AXCAN PHARMA INC | AXCA | NASDAQ | 16.54 | \$758 | | |
| 5.6519 | BIOCRYST PHARMACEUTICAL INC | BCRX | NASDAQ | 9.12 | \$279 | | |
| 3.2884 | BIOENVISION INC | BIVN | NASDAQ | 4.21 | \$180 | | |
| 4.6503 | CELL GENESYS INC | CEGE | NASDAQ | 3.00 | \$187 | | |
| 2.5837 | COLEY PHARMACEUTICAL GROUP | COLY | NASDAQ | 9.09 | \$250 | | |
| 2.8077 | CYTOKINETICS INC | CYTK | NASDAQ | 6.84 | \$326 | | |
| 4.1444 | DENDREON CORP | DNDN | NASDAQ | 3.70 | \$361 | | |
| 4.3585 | ENZON INC | ENZN | NASDAQ | 8.17 | \$360 | | |
| 3.2817 | GERON CORP | GERN | NASDAQ | 7.20 | \$515 | | |
| 6.7741 | GTX INC | GTXI | NASDAQ | 20.90 | \$739 | | |
| 4.6443 | HANA BIOSCIENCES INC. | HNAB | NASDAQ | 3.87 | \$71 | | |
| 5.9170 | ISIS PHARMACEUTICALS | ISIS | NASDAQ | 9.59 | \$845 | | |
| 3.6990 | KERYX BIOPHARMACEUTICALS | KERX | NASDAQ | 10.71 | \$480 | | |
| 3.9028 | MARSHALL EDWARDS INC | MSHL | NASDAQ | 3.76 | \$240 | | |
| 7.6910 | MERCK SERONO SA (ADR) | SRA | NYSE | 22.77 | \$13,786 | | |
| 4.7523 | PEREGRINE PHARMACEUTICALS INC | PPHM | NASDAQ | 0.99 | \$198 | | |
| 5.3793 | PROGENICS PHARMACEUTICALS INC | PGNX | NASDAQ | 23.84 | \$630 | | |
| 2.6157 | SHIRE PLC (ADR) | SHPGY | NASDAQ | 64.60 | \$11,772 | | |

^{*}Holdings are subject to change without notice. Maximum weighting for any security in an Underlying Index is typically 15%. When a company's weighting exceeds 15% of the overall Index portfolio, the Index Administrator will reduce such company's weighting to 10%, with the 5% "excess" applied equally to all remaining component securities in the Underlying Index. Minimum weighting for a security in an Underlying Index is 2.5%, if a security's weighting falls below 2.5%, the Index Administrator will increase the security's weighting to its initial weighting or 5%, whichever is less, with the required increment taken equally from all the remaining component securities.

■ EXCHANGE TRADED FUND INFORMATION



WHAT ARE EXCHANGE TRADED FUNDS?

An exchange traded fund (ETF) is an investment vehicle which offers shares that are listed on a national securities exchange. Shares of ETFs can be traded throughout the day on that stock exchange at market-determined prices. ETFs typically invest predominantly in the securities of companies comprising an underlying index. As such, the ETF itself is an index fund.

Because ETFs are priced and traded throughout the day like a stock, investors can buy or sell shares at any time during market trading hours of the exchange on which they trade. Just as with any common stock, investors can write stop losses and market orders. Brokerage commissions may apply. In general, ETFs feature low expense ratios and are tax efficient. ETFs can also be constructed to allow for options trading. ETFs are subject to risks similar to those of stocks including those regarding short-selling and margin account maintenance.

HOW CAN INVESTORS PURCHASE HEALTHSHARES™ ETFs?

Any investor can purchase or sell ETFs on the secondary market through a broker. When you buy or sell ETFs on the secondary market, your broker can charge a commission. In addition, because secondary-market transactions occur at market prices, you may pay more than Net Asset Value (NAV) when you buy ETFs, and receive less than NAV when you sell those ETFs.







"Standard & Poor's" is a trademark of The McGraw-Hill Companies, Inc.